Solu Therapeutics
Business Services · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
15 Necco St Fl 7, Boston, Massachusetts,...Phone Number
(781) 874-1100Website
www.solutherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Solu Therapeutics
Solu Therapeutics was established in May 2023 following the granting of an exclusive license to the CyTAC platform from GSK. The company is a clinical-stage company advancing the company's lead program through Phase 1 trials in chronic myelomonocytic leukemia, with additional CyTAC and TicTAC programs rapidly progressing toward development candidate status.Explore more
Solu Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Solu Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Solu Therapeutics launches new products
Funding: Get notified immidiatlly once Solu Therapeutics has new funding data
Check out if Solu Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Solu Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Solu Therapeutics recently announced quarterly report
Click to see if Solu Therapeutics had a recent Job posting/layoffs
Solu Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Solu Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Solu Therapeutics
Find 2 more new buyers
Company Profile Activity
Activity Insights
Solu Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Solu Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Solu Therapeutics.
Solu Therapeutics financials insights
Gather financial insights about Solu Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Angel/Seed
$31M
2025
Series A
$41M
Solu Therapeutics Tech Stack
A closer look at the technologies used by Solu Therapeutics
See more technologies
Most Recent Scoops
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Left Company
Executive Move
Solu Therapeutics News & Media
Solu Therapeutics Announces Presentation of Trial in Progress on STX-0712 for Treatment of Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting
BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that it will present details from its first-in-human Phase 1 clinical trial of...Solu Therapeutics Appoints Enda Moran, PhD, MBA as Chief Operating Officer
BOSTON, June 16, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Enda Moran, PhD, MBA as Chief Operating Officer (COO). "As...Solu Therapeutics Closes $41M Series A Financing and Announces First Patient Dosed in Phase 1 Clinical Trial of STX-0712 in Patients with CMML and Other Advanced Hematologic Malignancies
Funding to support clinical evaluation of STX-0712, drive additional pipeline programs, and target new applications of company's proprietary CyTAC™ and TicTAC™ platforms. Phase 1 trial of STX-0712 to assess safety and preliminary antitumor activity of novel CCR2-CyTAC therapy in patients...Solu Therapeutics Presents Positive Preclinical Data on STX-0712 for Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia at ASH Annual Meeting
STX-0712 showed robust activity against CCR2-positive monocytes in CMML and AML patient samples BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Solu Therapeutics
Sign Up For FreeTo access detailed company insights
Solu Therapeutics was established in May 2023 following the granting of an exclusive license to the CyTAC platform from GSK. The company is a clinical-stage company advancing the company's lead program through Phase 1 trials in chronic myelomonocytic leukemia, with additional CyTAC and TicTAC programs rapidly progressing toward development candidat... Read More
